ES2596855T3 - Inducción de tolerancia mucosa a antígenos - Google Patents

Inducción de tolerancia mucosa a antígenos Download PDF

Info

Publication number
ES2596855T3
ES2596855T3 ES06830192.8T ES06830192T ES2596855T3 ES 2596855 T3 ES2596855 T3 ES 2596855T3 ES 06830192 T ES06830192 T ES 06830192T ES 2596855 T3 ES2596855 T3 ES 2596855T3
Authority
ES
Spain
Prior art keywords
acid
ova
microorganism
autoimmune
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06830192.8T
Other languages
English (en)
Inventor
Pieter Rottiers
Veerle Snoeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrexon Actobiotics NV
Original Assignee
Intrexon Actobiotics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Actobiotics NV filed Critical Intrexon Actobiotics NV
Application granted granted Critical
Publication of ES2596855T3 publication Critical patent/ES2596855T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)

Abstract

Una combinación que comprende un microorganismo secretor de IL-10 y un alérgeno, aloantígeno, antígeno propio o autoantígeno para su uso en la inducción de tolerancia inmunitaria o para su uso en el tratamiento de una enfermedad elegida del grupo que consiste en una reacción alérgica que incluye alergia alimentaria, enfermedad celíaca, asma alérgica, uveítis autoinmunitaria, tiroiditis autoinmunitaria, miastenia gravis autoinmunitaria, artritis reumatoide, diabetes tipo I, esclerosis múltiple, enfermedad de injerto contra huésped, inmunoactivación de producto terapéutico, y producción de anticuerpos contra el Factor VIII no endógeno, en un mamífero.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
vida restante del mamífero); por ejemplo desde aproximadamente (2 o 3 o 5 días, 1 o 2 semanas, o 1 mes) hacia arriba y/o por ejemplo hasta aproximadamente (5 años, 1 año, 6 meses, 1 mes, 1 semana, o 3 o 5 días). Es típica la administración de la dosis de mantenimiento diaria durante de aproximadamente 3 a aproximadamente 5 días o durante de aproximadamente 1 semana a aproximadamente 1 año. Otros constituyentes de las formulaciones
5 líquidas pueden incluir conservantes, sales inorgánicas, ácidos, bases, tampones, nutrientes, vitaminas u otros productos farmacéuticos.
El microorganismo que secreta el compuesto inmunomodulador y/o el antígeno puede administrarse en una dosis de al menos 104 unidades formadoras de colonias (ufc) a 1012 ufc al día, preferiblemente entre 106 ufc y 1012 ufc al día,
10 lo más preferiblemente entre 109 ufc y 1012 ufc al día. Según el método descrito en Steidler y col. (Science 2000), el compuesto inmunomodulador de por ejemplo de 109 ufc se secreta hasta de al menos 1 ng a 100 ng. A través de ELISA, conocido por un experto en la técnica, el antígeno de, por ejemplo, de 109 ufc se secreta hasta de al menos 1 ng a 100 ng; el experto en la técnica puede calcular el intervalo de secreción de compuesto inmunomodulador y/o antígeno en relación con cualquier otra dosis de ufc.
15 El antígeno puede administrarse en una dosis que induce una respuesta a baja dosis. Preferiblemente, dicho antígeno se administra en una dosis de al menos 10 fg a 100 µg al día, preferiblemente entre 1 pg y 100 µg al día, lo más preferiblemente entre 1 ng y 100 µg al día.
20 El compuesto inmunomodulador de la invención puede administrarse en una dosis de al menos 10 fg a 100 µg al día, preferiblemente entre 1 pg y 100 µg al día, mucho más preferiblemente entre 1 ng y 100 µg al día.
Preferiblemente, los compuestos o la composición se proporcionan en una forma farmacéutica unitaria, por ejemplo un comprimido, una solución, una cápsula o una dosis de aerosol medida, de modo que se administra una dosis 25 única al sujeto, por ejemplo un paciente.
Dependiendo del modo de administración, por ejemplo oral, o cualquiera de los descritos anteriormente, el experto en la técnica conoce cómo definir o calcular la dosis real que va a administrarse a un paciente. El experto en la técnica tendrá conocimientos sobre cómo ajustar las dosis dependiendo del paciente, el microorganismo, el vector,
30 etc.
Los compuestos de la presente invención también pueden tomar la forma de una sal, hidrato, solvato o metabolito farmacológicamente aceptable. Las sales farmacológicamente aceptables incluyen sales básicas de ácidos orgánicos e inorgánicos, incluyendo, pero sin limitación, ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido 35 fosfórico, ácido nítrico, ácido metanosulfónico, ácido etanosulfónico, ácido p-toluenosulfónico, ácido naftalenosulfónico, ácido málico, ácido acético, ácido oxálico, ácido tartárico, ácido cítrico, ácido láctico, ácido fumárico, ácido succínico, ácido maleico, ácido salicílico, ácido benzoico, ácido fenilacético, ácido mandélico y similares. Cuando los compuestos de la invención incluyen una función ácida, tal como un grupo carboxilo, entonces los expertos en la técnica conocen bien pares catiónicos farmacéuticamente aceptables para el grupo carboxilo e
40 incluyen cationes alcalinos, alcalinotérreos, de amonio, de amonio cuaternario y similares.
El microorganismo puede ser cualquier microorganismo, incluyendo bacterias, levaduras u hongos, adecuados para administración mucosa. Preferiblemente, dicho microorganismo es un microorganismo no patógeno, incluso más preferiblemente dicho microorganismo es un microorganismo probiótico. El experto en la técnica conoce organismos 45 probióticos. Los organismos probióticos incluyen, pero sin limitación, bacterias tales como Lactobacillus sp., Lactococcus sp., y levaduras tales como Saccharomyces cerevisiae subspecies boulardii. Preferiblemente, dicha bacteria es una bacteria de ácido láctico; incluso más preferiblemente, dicha bacteria de ácido láctico se elige entre el grupo que consiste en Lactobacillus, Leuconostoc, Pediococcus, Lactococcus, Streptococcus, Aerococcus, Carnobacterium, Enterococcus, Oenococcus, Teragenococcus, Vagococcus y Weisella. En una realización preferida
50 adicional, dicho microorganismo es Lactococcus lactis. En otras realización preferida, dicho microorganismo es Saccharomyces cerevisiae.
En una realización preferida, la citocina inmunosupresora se combina con anticuerpos antagonizantes contra citocinas inmunoinductoras, tales como anti-IL-2, anti-IL-12 y/o anti-IFNγ; y moléculas coestimuladoras, tales como 55 anti-CD40L y anti-CD3. Como alternativa, pueden administrarse compuestos que estimulan la producción de las citocinas inmunosupresoras, tales como subunidad B de la toxina del cólera; y moléculas que estimulan la función de linfocitos T reguladores, tales como agonistas de CTLA-4 e ICOS. Como se ha descrito anteriormente, preferiblemente, dicho microorganismo es un microorganismo no patógeno, incluso más preferiblemente es un microorganismo probiótico. El experto en la técnica conoce organismos probióticos, e incluyen, pero sin limitación,
9
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
Dos modelos de ratón de asma alérgica que imita a la enfermedad humana son el modelo de alérgeno Ova y el modelo SCID humanizado.
El modelo de alérgeno Ova
5 Se exponen mediante inhalación ratones sensibilizados a OVA con aerosol de OVA que conduce a inflamación eosinofílica de las vías respiratorias dependiente de citocinas Th2, hiperreactividad bronquial y producción de IgE, hallazgos ampliamente característicos del asma alérgica humana (Brusselle, 1994, Clin Exp Allergy 24: 73; Kips y col. 1996, Am J Respir Crit Care Med 153: 535; Brusselle y col. 1995, Am J Respir Cell Mol Biol 12: 254).
10
Bacterias
Se usa la cepa MG1363 de L. lactis a lo largo de todo este estudio. Se cultivan las bacterias en medio GM17, es decir, M17 (Difco Laboratories, Detroit, MI) complementado con glucosa al 0,5 %. Se almacenan las suspensiones
15 madre de todas las cepas a -20 ºC en glicerol al 50 % en GM17. Para inoculaciones intragástricas, se diluyen las suspensiones madre 200 veces en GM17 nuevo y se incuban a 30 ºC. Alcanzaron una densidad de saturación de 2 x 109 unidades formadoras de colonias (UFC) por ml en el plazo de 16 horas. Se recogen las bacterias mediante centrifugación y se concentran 10 veces en medio BM9. Para el tratamiento, cada ratón recibe 100 µl de esta suspensión diariamente mediante catéter intragástrico.
20
Plásmidos
Se recupera la secuencia de ARNm que codifica para ovoalbúmina de Gallus gallus de Genbank (número de registro AY223553). Se aísla ARN total de útero de pollo y se sintetiza ADNc usando 2 µg de ARN total, cebadores de oligo
25 dT2 µM (Promega Corporation Benelux, Leiden, Países Bajos), DTT 0,01 mM (Sigma-Aldrich, Zwijndrecht, Países Bajos), dNTP 0,5 mM (Invitrogen, Merelbeke, Bélgica), 20 U de Rnasin (Promega Incorporation Benelux) y 100 U de transcriptasa inversa Superscript II (Invitrogen) en un volumen de 25 µl. Se amplifica el fragmento de ADNc de OVA mediante reacción en cadena de la polimerasa (PCR) usando las siguientes condiciones: 94 ºC durante 2 min seguido de 30 ciclos a 94 ºC durante 45 segundos, 62 ºC durante 30 segundos y 72 ºC durante 90 segundos, con los
30 siguientes cebadores directo e inverso 5'-GGCTCCATCGGTGCAGCAAGCATGGAATT-3' y 5'-ACTAGTTAAGGGGAAAC-ACATCTGCCAAAGAAGAGAA-3'.
Se fusiona el fragmento amplificado a la señal de secreción Usp45 del vector pT1NX resistente a eritromicina, en el 35 sentido de 3' del promotor P1 de lactococos.
Las cepas MG1363 transformadas con plásmidos que portan IL-10 murina y ADNc de OVA se designan LL-IL10 y LL-OVA. LL-pT1NX, que es MG1363 que contiene el vector vacío pT1NX, sirven como control.
40 Cuantificación de OVA
Se determina OVA a partir de LL-OVA usando un ensayo inmunoabsorbente ligado a enzimas (ELISA) específico de OVA desarrollado en el laboratorio. También se evalúa la producción de las proteínas recombinantes mediante análisis de transferencia de tipo Western.
45
El modelo de alérgeno OVA
Ratones
50 Se adquieren ratones BALB/c (de 6 a 8 semanas de edad) de Charles River Laboratories (Calco, Italia). Se mantienen los ratones en condiciones libres de patógenos específicos.
Inmunización de los ratones
55 Se inmunizan los ratones por vía i.p. con 2 µg de OVA (calidad V; Sigma-Aldrich) en 2 mg de hidróxido de aluminio (alumbre). Se repite esta inmunización tras un intervalo de 10 días (en los días 0 y 10). Los ratones control reciben una inyección de solución salina en lugar de la disolución de OVA/alumbre. Siete días tras la inmunización, los ratones sensibilizados inhalan una disolución aerosolizada de OVA al 3 % disuelta en PBS durante 10 min. Se realiza la inhalación de OVA durante 3 días en una fila (días 18, 19, y 20). Los ratones control inhalan PBS solo en
18
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES06830192.8T 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antígenos Active ES2596855T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05111467 2005-11-29
EP05111467 2005-11-29
PCT/EP2006/069062 WO2007063075A1 (en) 2005-11-29 2006-11-29 Induction of mucosal tolerance to antigens

Publications (1)

Publication Number Publication Date
ES2596855T3 true ES2596855T3 (es) 2017-01-12

Family

ID=37889980

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06830192.8T Active ES2596855T3 (es) 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antígenos
ES09169276T Active ES2405552T3 (es) 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09169276T Active ES2405552T3 (es) 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos

Country Status (13)

Country Link
US (5) US8748126B2 (es)
EP (3) EP1957100B1 (es)
JP (2) JP5410759B2 (es)
CN (1) CN101316611B (es)
AU (1) AU2006319216B2 (es)
BR (1) BRPI0619206A2 (es)
CA (1) CA2631598C (es)
DK (1) DK2119450T3 (es)
ES (2) ES2596855T3 (es)
HK (1) HK1231371A1 (es)
PT (1) PT2119450E (es)
RU (1) RU2420569C2 (es)
WO (1) WO2007063075A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8748126B2 (en) * 2005-11-29 2014-06-10 Actogenix N.V. Induction of mucosal tolerance to antigens
ES2804472T3 (es) 2005-12-13 2021-02-08 Harvard College Estructuras para trasplante celular
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
WO2008071751A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
FI20075539L (fi) * 2007-07-12 2009-01-13 Valio Oy Maitohappobakteerit, joilla on proinflammatorisia ominaisuuksia
EP2254602B1 (en) 2008-02-13 2018-11-21 President and Fellows of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
SI2153841T2 (sl) 2008-08-15 2016-02-29 Circassia Limited Cepivo, ki obsega peptide Amb a 1, za uporabo pri zdravljenju alergije na ambrozijo
EP2331124A1 (en) 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
WO2010056143A1 (en) * 2008-11-13 2010-05-20 Instituto De Medicina Molecular The use of adjuvant to facilitate the induction of immune tolerance
JP5746053B2 (ja) 2009-02-05 2015-07-08 サーカッシア リミテッド ワクチン用ペプチド
US10617640B2 (en) 2009-07-07 2020-04-14 The Research Foundation For The State University Of New York Phosphoserine containing compositions for immune tolerance induction
EP2451485B1 (en) * 2009-07-07 2016-03-02 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance
US8728456B2 (en) * 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US20110081320A1 (en) * 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
US20130058898A1 (en) 2010-03-10 2013-03-07 Kaneka Corporation Lactic acid bacterium-containing preparation
WO2011150235A1 (en) * 2010-05-27 2011-12-01 Allertein Therapeutics, Llc Methods and reagents for treating autoimmune disorders and/or graft rejection
US11202759B2 (en) 2010-10-06 2021-12-21 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP2701745B1 (en) 2011-04-28 2018-07-11 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
JP6062426B2 (ja) 2011-06-03 2017-01-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ インサイチュー抗原生成癌ワクチン
RU2653757C2 (ru) 2011-09-23 2018-05-14 Интрексон Актобиотикс Н.В. Модифицированные грамположительные бактерии и их применение
ES2676707T3 (es) 2011-09-23 2018-07-24 Intrexon Actobiotics Nv Bacterias gram positivas modificadas y usos de las mismas
BR112014018035A8 (pt) * 2012-02-08 2017-07-11 Premune Ab Prevenção de doenças inflamatórias em mamíferos domésticos exceto humanos
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
WO2013176916A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
JP6219728B2 (ja) * 2014-01-15 2017-10-25 キッコーマン株式会社 Ｆｏｘｐ３陽性制御性Ｔ細胞とＩＦＮ−γ産生ＩＬ−１０産生Ｔ細胞誘導を指標とした、経口免疫寛容物質スクリーニング方法及び経口免疫寛容増強組成物
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3909603A1 (en) * 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Glycotargeting therapeutics
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
EP2989904A1 (en) * 2014-07-29 2016-03-02 Heinrich-Heine-Universität Induction of immunological tolerance using yeast
KR101662898B1 (ko) * 2014-09-02 2016-10-06 서울대학교산학협력단 점막점착성 고분자 및 이의 용도
WO2016102660A1 (en) 2014-12-23 2016-06-30 PHILLIPSON, Mia Methods for wound healing
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
EP3081227A1 (en) * 2015-04-15 2016-10-19 Institut National De La Recherche Agronomique Lactococcus lactis producing tslp or il-25 and their uses as probiotics and therapeutics
US10857190B2 (en) * 2015-10-06 2020-12-08 Albert Einstein College Of Medicine Microbial hyperswarmers and uses thereof
CN115531609A (zh) 2016-02-06 2022-12-30 哈佛学院校长同事会 重塑造血巢以重建免疫
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2018042390A1 (en) 2016-09-02 2018-03-08 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing il-10 and insulin
CN109983028B (zh) 2016-09-13 2023-10-20 英特瑞克斯顿阿克图比奥帝克斯有限公司 黏膜黏附性微生物
CN108114272A (zh) * 2016-11-28 2018-06-05 上海市第五人民医院 一种构建哮喘免疫耐受模型的方法
JP2020535809A (ja) * 2017-09-29 2020-12-10 ナントセル，インコーポレイテッド 抗原タンパク質及びそのための方法
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
JP2020000033A (ja) * 2018-06-26 2020-01-09 国立大学法人広島大学 経口免疫寛容誘導剤、これを含有する食品および医薬品、ならびに加工食品の製造方法
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
CN110408579A (zh) * 2019-06-03 2019-11-05 东北农业大学 牛白细胞介素-2重组乳酸菌及其应用
EP4034144A1 (en) 2019-09-27 2022-08-03 Intrexon Actobiotics NV d/b/a Precigen Actobio Treatment of celiac disease
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100495A (en) 1975-11-27 1978-07-11 Cselt - Centro Studi E Laboratori Telecomunicazioni Adaptive method of and means for recovering digital signals
US4190495A (en) 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4874702A (en) 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US4888170A (en) 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5032510A (en) 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
EP0176320B1 (en) 1984-09-26 1990-07-25 Eli Lilly And Company A method for expression and secretion in bacillus
US5591632A (en) 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
WO1988006626A1 (en) 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5330753A (en) 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
IE892131A1 (en) 1989-06-30 1991-01-02 Univ Cork Marker genes for genetic manipulation
US5149532A (en) 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
DE4006521A1 (de) 1990-03-02 1991-09-05 Bayer Ag Zuckerhaltige polymere zur umhuellung und einbettung von arzneistoffen
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
IL99097A0 (en) 1990-09-05 1992-07-15 Akzo Nv Haemophilus paragallinarum vaccine
KR100240182B1 (ko) 1991-03-05 2000-01-15 레슬리 제인 에드워즈 재조합 단백질을 발헨하는 약독해진 박테리아를 함유하는 백신
ATE216253T1 (de) 1991-10-07 2002-05-15 Brigham & Womens Hospital Verfahren zur erhöhung der darmabsorption
IL103530A0 (en) 1991-10-25 1993-03-15 Duphar Int Res Treponema hyodysenteriae vaccine
GB2278358B (en) 1992-02-27 1995-07-26 Lynxvale Ltd Heterologous gene expression in Lactococcus,and the expression products therefrom
US5455034A (en) 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
DE4231764A1 (de) 1992-09-23 1994-03-24 Inst Pflanzengenetik & Kultur Verfahren zur chromosomalen Integration eines Produkt-Gens
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5691185A (en) 1993-10-08 1997-11-25 Chr. Hansen A/S Lactic acid bacterial suppressor mutants and their use as selective markers and as means of containment in lactic acid bacteria
BR9407813A (pt) 1993-10-13 1997-05-06 Gx Biosystems As Nucleases de staphylococcus recombinantes e seu uso na limitação da sobrevivencia de microorganismos elaborados por engenharia genética
IT1270123B (it) 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
AU2149495A (en) 1995-04-11 1996-10-30 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacte ria like lactobacillus such that the bacteria can efficientl y express, secrete and display proteins at the surface
US5753622A (en) 1995-05-10 1998-05-19 University Technologies International, Inc. Use of epidermal growth factor as a gastrointestinal therapeutic agent
EP0832255B1 (en) 1995-06-07 2005-12-14 Washington University Recombinant bacterial system with environmentally limited viability
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9518323D0 (en) 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
EP0921816A4 (en) * 1996-03-28 2004-09-22 Whitehead Biomedical Inst CELLS WITH INCREASED OPSONINE CONTENT AND METHOD FOR REGULATING AN IMMUNE RESPONSE TO ANTIQUE
WO1997038688A1 (en) 1996-04-12 1997-10-23 Peptide Technology Pty. Limited Methods of treating immunopathologies using polyunsaturated fattyacids
DE69736226T2 (de) 1996-04-19 2006-11-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren
US5972887A (en) 1996-09-19 1999-10-26 The Nemours Foundation Treatment of intestinal epithelial cell malfunctions with Hepatocyte Growth Factor
US5723245A (en) 1996-10-09 1998-03-03 Xerox Corporation Colored toner and developer compositions and process for enlarged color gamut
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
GB9700939D0 (en) 1997-01-17 1997-03-05 Microbial Technics Limited Therapy
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
DK0892054T3 (da) 1997-06-20 2007-04-02 Intervet Int Bv Clostridium perfringens-vaccine
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
DK1075512T3 (da) 1998-05-07 2010-06-07 Univ Bruxelles Cytotoxinbaseret biologisk indkapsling
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
KR100695562B1 (ko) 1998-09-28 2007-03-15 워너-램버트 캄파니 엘엘씨 Ｈｐｍｃ 캡슐을 이용한 장 및 결장에의 전달방법
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
JP4598954B2 (ja) 1998-10-20 2010-12-15 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用
DE60031405T2 (de) 1999-07-05 2007-08-16 Actogenix Nv Bereitstellung von peptiden mit kleeblattstruktur
WO2002033109A2 (en) 2000-10-20 2002-04-25 Bioteknologisk Institut Fermentation method for production of heterologous gene products in lactic acid bacteria
ATE331789T1 (de) * 2001-05-03 2006-07-15 Vlaams Interuniv Inst Biotech Selbsterhaltender lactococcus stamm
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
NO318426B1 (no) 2001-10-02 2005-04-18 Neurozym Biotech As Et materiale for a senke konsentrasjonen av patogene tarmpeptider
EP1319410A1 (en) 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Use of micro-organisms for a directed delivery of substances to specific parts of the gut
US20040043003A1 (en) 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
DE10208653A1 (de) 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
WO2003096979A2 (en) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
EP1364586A1 (en) * 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
AU2003250250B2 (en) 2002-06-19 2008-02-14 Intrexon Actobiotics Nv Methods and means to promote gut absorption
AU2003298291A1 (en) 2002-11-15 2004-06-15 Universiteit Gent Self-containing lactobacillus strain
DK1563300T3 (da) 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostisk fremgangsmåde til cøliaki
JP4589618B2 (ja) 2003-11-28 2010-12-01 独立行政法人農業生物資源研究所 免疫調節性機能を誘導する乳酸菌類とその成分
WO2005076965A2 (en) * 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
CN1695469A (zh) 2005-05-17 2005-11-16 田星 一种风味益生发酵乳及其制作方法
US8748126B2 (en) 2005-11-29 2014-06-10 Actogenix N.V. Induction of mucosal tolerance to antigens
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.

Also Published As

Publication number Publication date
CN101316611A (zh) 2008-12-03
CA2631598C (en) 2017-06-27
CA2631598A1 (en) 2007-06-07
PT2119450E (pt) 2013-04-26
US10195269B2 (en) 2019-02-05
EP1957100A1 (en) 2008-08-20
US20100172920A1 (en) 2010-07-08
US9526750B2 (en) 2016-12-27
EP1957100B1 (en) 2016-07-13
DK2119450T3 (da) 2013-05-06
EP2119450A2 (en) 2009-11-18
WO2007063075A1 (en) 2007-06-07
US9539291B2 (en) 2017-01-10
HK1231371A1 (zh) 2017-12-22
EP3097924B1 (en) 2020-01-08
CN101316611B (zh) 2017-05-03
EP3097924A1 (en) 2016-11-30
US8398995B2 (en) 2013-03-19
US20140322266A1 (en) 2014-10-30
RU2420569C2 (ru) 2011-06-10
AU2006319216A1 (en) 2007-06-07
US20170100475A1 (en) 2017-04-13
EP2119450B1 (en) 2013-02-13
AU2006319216B2 (en) 2012-09-13
US8748126B2 (en) 2014-06-10
ES2405552T3 (es) 2013-05-31
RU2008126198A (ru) 2010-01-10
BRPI0619206A2 (pt) 2011-09-20
JP5410759B2 (ja) 2014-02-05
JP2013189446A (ja) 2013-09-26
JP2009521406A (ja) 2009-06-04
US20140322230A1 (en) 2014-10-30
US20090148389A1 (en) 2009-06-11
EP2119450A3 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
ES2596855T3 (es) Inducción de tolerancia mucosa a antígenos
US10500237B2 (en) Compositions comprising bacterial strains
EP3204025B1 (en) Compositions comprising bacterial strains
Sun et al. Display of Eimeria tenella EtMic2 protein on the surface of Saccharomyces cerevisiae as a potential oral vaccine against chicken coccidiosis
ES2492468T3 (es) Tratamiento de enfermedad inmunitaria por administración a través de la mucosa de antígenos usando Lactobacillus genéticamente modificado
Kim et al. Involvement of IL-10 in peroxisome proliferator-activated receptor γ-mediated anti-inflammatory response in asthma
ES2353721T3 (es) Administración y producción controladas de agentes biológicamente activos mediante bacterias intestinales.
Chang et al. Alteration of IL-17 related protein expressions in experimental autoimmune myocarditis and inhibition of IL-17 by IL-10-Ig fusion gene transfer
ES2924990T3 (es) Inducción de tolerancia específica de antígeno
Charng et al. Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria
Yang et al. Construction and immunological evaluation of recombinant Lactobacillus plantarum expressing SO7 of Eimeria tenella fusion DC-targeting peptide
JP2009534029A (ja) 組換え乳酸桿菌およびその使用
Mitsui et al. Salmon cartilage proteoglycan suppresses mouse experimental colitis through induction of Foxp3+ regulatory T cells
TW201514198A (zh) 治療或預防結核病的組合物及方法
CN105979957A (zh) 细菌通过模拟α-MSH的CLPB蛋白对宿主进食与情绪的影响
Guan et al. Targeting IL‐23 by employing a p40 peptide‐based vaccine ameliorates murine allergic skin and airway inflammation
Cheng et al. Blockade of IL-23 ameliorates allergic lung inflammation via decreasing the infiltration of Tc17 cells
CN102573897A (zh) 使用副粘病毒载体的经鼻喷雾型结核疫苗
Sun et al. Immunological effects of recombinant lactobacillus casei expressing IHNV G protein and rainbow trout (Oncorhynchus mykiss) chemokine CK6 as an oral vaccine
Kajikawa et al. Adjuvant effects for oral immunization provided by recombinant Lactobacillus casei secreting biologically active murine interleukin-1β
Chen et al. A bovine whey protein extract can induce the generation of regulatory T cells and shows potential to alleviate asthma symptoms in a murine asthma model
Xie et al. The immunomodulator AS101 suppresses production of inflammatory cytokines and ameliorates the pathogenesis of experimental autoimmune encephalomyelitis
Xu et al. Intranasal administration of recombinant mycobacterium smegmatis inducing IL-17A autoantibody attenuates airway inflammation in a murine model of allergic asthma
Eichinger et al. Prior respiratory syncytial virus infection reduces vaccine-mediated Th2-skewed immunity, but retains enhanced RSV F-specific CD8 T cell responses elicited by a Th1-skewing vaccine formulation
US9999663B2 (en) Immunogenic formulation containing recombinant live BCG that express antigens of metapneumovirus (hMPV), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use